Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06734832Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)Sinovac Biotech Co., Ltd · Hand, Foot, and Mouth Disease(HFMD)RecruitingSVALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05065216Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)DiaMedica Therapeutics Inc · Acute StrokeRecruitingDMACLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06274801Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Gossamer Bio USA, Inc. · Pulmonary Arterial HypertensionRecruitingGOSSLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06413433Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolAxsome Therapeutics, Inc. · Binge-Eating DisorderRecruitingAXSMLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06568367Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)Axsome Therapeutics, Inc. · Excessive SleepinessRecruitingAXSMLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07016750A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaRecruitingKRYSLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseVanda Pharmaceuticals · Nausea and VomitingRecruitingVNDALead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer · Lyme DiseaseRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Psychosis Associated With Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 9, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Alzheimer DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07645248A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and...GlaxoSmithKline · AsthmaRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Dec 28, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05789056Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT06953466Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07505836Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsSinovac Biotech Co., Ltd · Epidemic MeningitisRecruitingSVALead
- Enrollment
- Locked
- Primary completion
- Jan 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05254171Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPanbela Therapeutics, Inc. · Pancreatic Cancer MetastaticRecruitingPBLALead
- Enrollment
- Locked
- Primary completion
- Aug 29, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 7, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05319353A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of...Takeda · Cytomegalovirus (CMV)RecruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Jan 18, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT07355075A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate...Turn Therapeutics · Eczema Atopic DermatitisRecruitingTTRXLead
- Enrollment
- Locked
- Primary completion
- Jan 20, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05877963Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabTG Therapeutics, Inc. · Relapsing Multiple SclerosisRecruitingTGTXLead
- Enrollment
- Locked
- Primary completion
- Jan 21, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07653100A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFPfizer · Respiratory Syncytial Virus (RSV)RecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Jan 25, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04817618Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Novartis Pharmaceuticals · C3GRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06855160A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine...GlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Sep 10, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 23 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.